8-K: Kronos Bio Receives Nasdaq Non-Compliance Notice Due to Low Share Price

Kronos Bio has been notified by Nasdaq that it is not in compliance with listing rules due to its stock price falling below $1.00 for 30 consecutive days.

Summary

• Kronos Bio received a notice from Nasdaq on November 4, 2024, stating that the company is not compliant with Nasdaq's Listing Rule 5450(a)(1).
• The non-compliance is due to the company's common stock price being below $1.00 per share for 30 consecutive business days.
• This notification does not immediately affect the listing or trading of Kronos Bio's stock on the Nasdaq Global Select Market.
• Kronos Bio has 180 calendar days, until May 5, 2025, to regain compliance by having its stock price meet or exceed $1.00 for at least ten consecutive business days.
• If the company fails to regain compliance by May 5, 2025, it may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market.
• To transfer to the Nasdaq Capital Market, Kronos Bio would need to meet all initial listing standards except the bid price requirement and provide written notice of its intention to cure the deficiency, potentially through a reverse stock split.
• If the company fails to regain compliance or transfer to the Nasdaq Capital Market, it could face delisting from Nasdaq.
• Kronos Bio intends to monitor its stock price and consider options to regain compliance, but there is no guarantee it will be successful.

Sentiment

Score: 3

Explanation: The document indicates a negative situation with the company's stock price and potential delisting, which is concerning for investors.

Positives

• The notification of non-compliance does not immediately affect the listing or trading of the company's stock.
• Kronos Bio has a 180-day grace period to regain compliance.
• An additional 180-day compliance period is possible by transferring to the Nasdaq Capital Market.

Negatives

• The company's stock price has been below $1.00 for 30 consecutive business days, triggering the non-compliance notice.
• There is no guarantee that the company will be able to regain compliance with Nasdaq's listing requirements.
• Failure to regain compliance could lead to delisting from Nasdaq.

Risks

• The company's stock price may not recover to above $1.00 within the given time frame.
• The company may not be able to meet the requirements for transferring to the Nasdaq Capital Market.
• There is a risk of delisting from Nasdaq if compliance is not achieved.
• A reverse stock split may negatively impact shareholder value.

Future Outlook

The company intends to actively monitor its stock price and consider available options to regain compliance with the listing requirements, but there is no assurance of success.

Management Comments

• The company intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the listing requirements.

Industry Context

This type of non-compliance notice is not uncommon for companies whose stock price has declined significantly, and it highlights the importance of maintaining a healthy stock price to remain listed on major exchanges.

Comparison to Industry Standards

• Many biotech companies, especially those in the development stage, can experience stock price volatility and may face similar challenges with maintaining listing compliance.
• Companies like Geron Corporation (GERN) and Agenus Inc. (AGEN) have faced similar delisting risks in the past due to low stock prices.
• The 180-day grace period is a standard procedure for Nasdaq, and the option to transfer to the Capital Market is also a common pathway for companies seeking more time to regain compliance.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment.
• Employees may be concerned about the company's future.
• The company's reputation may be negatively impacted.

Next Steps

• Kronos Bio will monitor its stock price.
• Kronos Bio will consider options to regain compliance with Nasdaq listing requirements.
• Kronos Bio may consider a reverse stock split if it transfers to the Nasdaq Capital Market.

Key Dates

Keywords

Nasdaq, non-compliance, listing rule, minimum bid price, delisting, reverse stock split, KRON, stock price